Høhloch, Karin

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T08:50:15Z"],["dc.date.available","2018-11-07T08:50:15Z"],["dc.date.issued","2011"],["dc.description.abstract","A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-131-anti-CD20 antibody (I-131-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed (n=14) and refractory (n=2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 (n=4), transformed follicular (FL 3b; n=6), diffuse large B-cell (DLBCL; n=4), mantle cell (n=1) and marginal zone lymphoma (n=1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-131-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL."],["dc.identifier.doi","10.1007/s00277-011-1199-y"],["dc.identifier.isi","000296730300008"],["dc.identifier.pmid","21360108"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21653"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-131-anti-CD20 antibody and stem cell rescue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","181"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","eJHaem"],["dc.bibliographiccitation.lastpage","187"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Høhloch, Karin"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Buske, Christian"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Poeschel, Viola"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Altmann, Bettina"],["dc.date.accessioned","2020-12-11T11:48:55Z"],["dc.date.accessioned","2021-10-27T13:22:25Z"],["dc.date.available","2020-12-11T11:48:55Z"],["dc.date.available","2021-10-27T13:22:25Z"],["dc.date.issued","2020"],["dc.description.abstract","Serum albumin a well‐known risk factor predicting outcome in many solid tumors. We explore the role of low serum albumin (≤3.5 g/dL) as an independent risk factor in elderly patients with aggressive B‐cell lymphoma. Outcome of 429 patients treated with R‐CHOP‐14 in the RICOVER‐60 trial and available serum albumin were analyzed in this retrospective study. Of the 429 patients in the RICOVER‐60 trial, 137 (32%) had low and 292 (68%) had normal serum albumin levels (>3.5 g/dL). In the low albumin group, patients had significantly higher International Prognostic Index (IPI), bulky disease, extralymphatic involvement, and B‐symptoms. Event‐free survival (EFS) (P < .001), progression‐free survival (PFS) (P < .001), and overall survival (OS) (P < .001) were significantly inferior for patients with low compared to those with normal serum albumin. Multivariate analysis adjusted for IPI shows following Hazard ratios (HR) for low serum albumin: EFS (HR = 1.5; 95% confidance interval [CI] [1.1; 2.1], P = .009), PFS (HR = 1.7; 95% CI [1.2; 2.4], P = .001) and OS (HR = 1.6; 95% CI [1.1; 2.3], P = .006). Results were confirmed in 185 patients from the DENSE‐R‐CHOP‐14 and SMARTE‐R‐CHOP‐14 trials. In conclusion, low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma treated with R‐CHOP."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2020"],["dc.identifier.doi","10.1002/jha2.61"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17695"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92093"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","2688-6146"],["dc.relation.issn","2688-6146"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","5"],["dc.bibliographiccitation.journal","SpringerPlus"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Zwick, Carsten"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Hasenclever, Dirk"],["dc.contributor.author","Kaiser, Ulrich"],["dc.contributor.author","Engert, Andreas"],["dc.contributor.author","Hoeffkes, Heinz-Gert"],["dc.contributor.author","Kroschinsky, Frank"],["dc.contributor.author","Mesters, Rolf"],["dc.contributor.author","Feller, Andreas C."],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Pfreundschuh, Michael"],["dc.date.accessioned","2018-11-07T09:45:15Z"],["dc.date.available","2018-11-07T09:45:15Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Dose escalation and modification of CHOP has improved the prognosis of patients with aggressive lymphoma; even in the rituximab era, dose escalation for high-risk patients is exploited and frequently limited by drug toxicity. Idarubicin (Id) is a 4-demethoxy anthracycline analogue of daunorubicin with activity against lymphoma and has been reported to cause less cardiotoxicity than other anthracylines. The aim of this study was to replace doxorubicine with idarubicin in the CHOEP regimen and to find the maximum tolerable dose (MTD) of idarubicin based on hematotoxicity. Patients and methods: Between 11/96 and 09/98, 64 patients (pts) aged 18-75 yrs (pts. 18-60, LDH not elevated, >60 years all risk groups) with newly diagnosed aggressive lymphoma received 6 cycles of CIVEP-14 with an escalating dose of idarubicin, consisting of idarubicin (11-16 mg/m(2) d1) and standard doses of cyclophosphamide, vincristine, etoposide, and prednisone with G-CSF support. Results: 55 pts (median age 56 yrs) were evaluable for a final analysis with a median observation time of 9.3 years. The CR-rate was 77.4%; the 5 and 8-year-EFS rates were 46.4% (95% CI 32.5-60.3%) and 43.5% (29.4-57.6%), respectively, and the 5- and 8 yr OS rates were 64.6% (51.7-77.5%) and 59.9% (46.4-73.4%). 14/55 patients have died due to lymphoma progression, and 2/55 patients (3.6%) due to treatment related toxicity, 4/55 due to other causes (3 infections, 1 acute heart failure). In a matched pair analysis comparing CHOEP-14 and CIVEP-14, CIVEP-14 had a higher hematotoxicity with no significant differences in the event free and overall survival for the two regimens. Conclusions: Thus, idarubicin cannot be used instead doxorubicin even if its dose is escalated to achieve similar hematotoxicity. Doxorubicin remains the standard anthracycline for the treatment of aggressive NHL."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2014"],["dc.identifier.doi","10.1186/2193-1801-3-5"],["dc.identifier.isi","000358906400002"],["dc.identifier.pmid","24455463"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11752"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34573"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","2193-1801"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","749"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Clinical Pharmacology & Therapeutics"],["dc.bibliographiccitation.lastpage","757"],["dc.bibliographiccitation.volume","83"],["dc.contributor.author","Kuehne, Annett"],["dc.contributor.author","Sezer, Orhan"],["dc.contributor.author","Heider, Ulrike"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Muhlke, Sabine"],["dc.contributor.author","Niere, W."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Kaiser, R."],["dc.date.accessioned","2018-11-07T11:15:25Z"],["dc.date.available","2018-11-07T11:15:25Z"],["dc.date.issued","2008"],["dc.description.abstract","Melphalan is associated with severe side effects such as mucositis, diarrhea, and myelosuppression. We investigated how much the individual severity of these side effects is predicted by pharmacokinetics. In addition, we studied glutathione S-transferase GSTM1, GSTT1, and GSTP1 polymorphisms in relation to adverse events. A high interindividual pharmacokinetic variability was observed in 84 patients. There was a linear correlation between creatinine and melphalan clearance (P = 0.0004). Patients treated with a dose >= 70 mg/m(2) had a 23-fold increased risk to develop mucositis (P<0.001) and a 12-fold increased risk to develop diarrhea (P<0.001) compared with lower doses. The GSTP1 codon 105 polymorphism may be relevant for development of mucositis and the GSTT1 deletion may predict diarrhea, but these findings require confirmation. Melphalan-induced side effects were significantly dependent only on dose. Therapeutic drug monitoring or genotyping for GST does not appear to be very helpful in optimizing therapy with melphalan."],["dc.identifier.doi","10.1038/sj.clpt.6100336"],["dc.identifier.isi","000255288100023"],["dc.identifier.pmid","17914442"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6076"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54361"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0009-9236"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","538"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.lastpage","544"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Zwick, C."],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Hohloch, K."],["dc.contributor.author","Schmits, R."],["dc.contributor.author","Mohren, M."],["dc.contributor.author","Liersch, R."],["dc.contributor.author","Bentz, M."],["dc.contributor.author","Graeven, U."],["dc.contributor.author","Wruck, U."],["dc.contributor.author","Hoffmann, M."],["dc.contributor.author","Metzner, B."],["dc.contributor.author","Hasenclever, D."],["dc.contributor.author","Loeffler, M."],["dc.contributor.author","Pfreundschuh, M."],["dc.date.accessioned","2019-07-09T11:53:01Z"],["dc.date.available","2019-07-09T11:53:01Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support. Patients and methods: Randomized phase I/II multicenter four-level (cyclophosphamide: 1000–1200–1400–1600 mg/m2; doxorubicin: 55–60–65–70 mg/m2; etoposide: 375–450–525–600 mg/m2) dose escalation study with CHOEP-14 and CHOEP-21 in young patients (18–60 years) with newly diagnosed aggressive non-Hodgkin’s lymphoma. Dose-limiting toxicity was defined as thrombocytopenia <80 000/mm3 and leukocytopenia <2500/mm3 on days 16 (CHOEP-14) and 23 (CHOEP-21) or prolonged (>4 days) leukocytopenia (<1000/mm3) or thrombocytopenia (<20 000/mm3). Results: One hundred and thirty-nine patients (high-CHOEP-14: 47, high-CHOEP-21: 92) were randomly allocated to the study. Maximal tolerated dose was level 2 for CHOEP-14 and level 4 for CHOEP-21. With a less favorable profile of patients in CHOEP-14, 4-year event-free survival was 47.9% after high-CHOEP-14 and 66.2% after high-CHOEP- 21, 4-year overall survival 62.1% after high-CHOEP-14 and 73.4% after high-CHOEP-21, respectively. Conclusion: Significant dose escalations of CHOEP are possible with granulocyte colony-stimulating factor support, with different chemotherapy models favoring the maximally escalated bi- or tri-weekly regimen, respectively. Because a higher total dose can be achieved with six cycles of the tri-weekly compared with the biweekly regimen, CHOEP-21 at dose escalation level 3 was chosen for a nationwide randomized comparison with baseline CHOEP-21 in a subsequent phase III trial."],["dc.identifier.doi","10.1093/annonc/mdm497"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6328"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60319"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Neurology"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Orlik, Lea"],["dc.contributor.author","Venzin, Reto"],["dc.contributor.author","Fehr, Thomas"],["dc.contributor.author","Hohloch, Karin"],["dc.date.accessioned","2020-12-10T18:38:53Z"],["dc.date.available","2020-12-10T18:38:53Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1186/s12883-019-1393-4"],["dc.identifier.eissn","1471-2377"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16285"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77467"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Cerebral salt wasting in a patient with myeloproliferative neoplasm"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Trials"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Dreyling, Martin"],["dc.contributor.author","Dürig, Jan"],["dc.contributor.author","Engelhard, Marianne"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Viardot, Andreas"],["dc.contributor.author","Witzens-Harig, Mathias"],["dc.contributor.author","Kieser, Meinhard"],["dc.contributor.author","Klapper, Wolfram"],["dc.contributor.author","Pott, Christiane"],["dc.contributor.author","Herfarth, Klaus"],["dc.date.accessioned","2020-12-10T18:39:05Z"],["dc.date.available","2020-12-10T18:39:05Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1186/s13063-019-3614-y"],["dc.identifier.eissn","1745-6215"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16373"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77537"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]